Related Experiment Video

Updated: Aug 11, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Reversing drug resistance in vivo

Hans-Guido Wendel1, Scott W Lowe

  • 1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.

Cell Cycle (Georgetown, Tex.)
|June 11, 2004
PubMed

Insights

Bcl-2, Akt, and eIF4E proteins drive cancer growth and drug resistance. Targeting mTOR with rapamycin can reverse resistance, but eIF4E can block this effect, emphasizing personalized cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Apoptotic defects are crucial in cancer development and drug resistance.
  • Bcl-2, Akt, and eIF4E are implicated in lymphomagenesis and drug resistance, cooperating with Myc.
  • Understanding these molecular interactions is key to overcoming therapeutic challenges.

Purpose of the Study:

  • To investigate the cooperative roles of Bcl-2, Akt, and eIF4E in lymphomagenesis and drug resistance.
  • To evaluate the efficacy of the mTOR inhibitor rapamycin in sensitizing tumors to chemotherapy.
  • To explore the impact of eIF4E on rapamycin's therapeutic effects and identify strategies to reverse drug resistance.

Main Methods:

  • In vivo studies using mouse models of lymphoma.
  • Analysis of protein expression (Bcl-2, Akt, eIF4E, Myc).
  • Assessment of chemotherapy-induced apoptosis and drug resistance.
  • Evaluation of rapamycin's effects on tumor response, with and without eIF4E modulation.

Main Results:

  • Bcl-2, Akt, and eIF4E cooperate with Myc in driving lymphomagenesis and conferring drug resistance.
  • Rapamycin sensitizes Akt-expressing lymphomas to chemotherapy-induced apoptosis.
  • eIF4E counteracts the sensitizing effect of rapamycin, highlighting its role in resistance.
  • Tumor genotype significantly influences response to targeted therapies.

Conclusions:

  • Translational deregulation plays a significant role in cancer development and drug resistance.
  • Targeting mTOR with rapamycin is a potential strategy to reverse drug resistance, but eIF4E activity must be considered.
  • Personalizing cancer therapy based on specific tumor molecular profiles (genotype) is essential for effective treatment.

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Drug Elimination by Renal Route: Tubular Reabsorption01:22

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...